FDA Expedited Approval Process Raises Concerns About Risks

Share this post

The Breakthrough Therapy designation, which expedites drug approvals, frequently relies on limited evidence and surrogate markers as primary endpoints.
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply